Full Breakdown
Supreme Court Stays 5th Circuit Ruling, Preserving Mail-Order Access to Mifepristone
5/20/2026, 2:08:51 AM
The Immediate Ruling
On May 14 2026 the U.S. Supreme Court issued an unsigned order staying the 5th U.S. Circuit Court of Appeals’ May 1 decision that would have required the abortion medication mifepristone to be dispensed only in-person. The stay leaves in place the Food and Drug Administration’s 2023 rule allowing telehealth prescriptions and mailing of the drug while the underlying lawsuit filed by Louisiana against the FDA proceeds in lower courts.
Legal and Regulatory Background
Mifepristone received FDA approval in 2000 and is authorized in 96 countries. In 2021 the FDA, citing pandemic-era data, removed the in-person dispensing requirement; the rule became permanent in 2023. Louisiana, a state with a total abortion ban, sued the agency in October 2025, arguing that the rule undermines state law and that the FDA’s safety review was inadequate. The manufacturers Danco Laboratories and GenBioPro intervened on the FDA’s side and sought emergency appeals after the 5th Circuit’s May 1 order.
Timeline of Key Events
- Oct 2023: FDA finalizes telehealth rule for mifepristone.
- Oct 2025: Louisiana files suit against the FDA.
- May 1 2026: 5th Circuit blocks mail-order and telehealth prescribing.
- May 4 2026: Supreme Court grants a temporary pause on the 5th Circuit order.
- May 14 2026: Court extends the stay indefinitely; no opinion is released.
Scale of Medication Abortion
- Approximately 65 % of U.S. abortions are medication-based; 25 % of those are prescribed via telemedicine.
- The risk of serious complications is < 1 %; combined mifepristone-misoprostol regimens are 93-99 % effective.
- In states with total bans, nearly 60 % of abortions are obtained through telehealth channels.
Principal Actors
- Justice Clarence Thomas and Justice Samuel Alito – dissenting justices.
- Louisiana Attorney General – plaintiff.
- FDA – defendant, currently reviewing the rule.
- Danco Laboratories and GenBioPro – manufacturers and appellants.
- Advocacy groups: Center for Reproductive Rights, Plan C, Avow Texas, Texas Values.
Official Statements & Responses
- The Supreme Court’s order was unsigned and provided no rationale, signaling a procedural stay rather than a substantive judgment.
- The FDA indicated that its ongoing safety review will inform any future regulatory change.
- The Trump administration’s Justice Department declined to file a brief, a move described by former HHS counsel Samuel Bagenstos as “shocking.”
- The Center for Reproductive Rights emphasized that telehealth “is critically important for people facing intimate-partner violence or lacking transportation.”
Criticism & Opposition
- Pro-life leaders, including Texas Values president Jonathan Saenz, condemned the stay as “murder by mail,” arguing the pill “causes the death of a baby” and is unsafe.
- Pro-choice advocates, such as Avow Texas director Ja’Loni Owens, hailed the decision as “very much in alignment with what we already know about mifepristone, which is very safe.”
On-the-Ground Perspectives
- Autumn Katz (Center for Reproductive Rights) noted that telehealth “allows people facing intimate-partner violence … to obtain medication safely.”
- Melissa Grant (Carafem) described the legal battle as “a giant chess game” requiring constant adaptation.
Why It Matters
Preserving mail-order access safeguards a primary abortion pathway for marginalized groups—rural residents, low-income patients, people with disabilities, and survivors of domestic abuse—who otherwise would face travel barriers in states where clinics have shuttered. A reversal could strain the limited clinic network, increase out-of-state travel costs, and exacerbate health inequities.
Conflicting Reports & Gaps
- The Supreme Court’s order offers no explanation of its reasoning, leaving the legal basis for the stay unclear.
- Justices Thomas and Alito invoke the 19th-century Comstock Act, yet scholars cited in the sources argue the Act does not categorically ban mailing abortion medication.
- No definitive stance has been issued on whether the FDA’s pending safety review will alter the telehealth rule.
Verbatim Quotes
- “the perpetration of a scheme to undermine our decision in Dobbs” — Justice Samuel Alito
- “They cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes,” — Justice Clarence Thomas
- “I mean, I think that the decision is very much in alignment with what we already know about mifepristone, which is that it is very safe,” — Ja’Loni Owens, Avow Texas
- “And I think a lot of people figured the court needed a week or so, a little bit of time, just to come up with the right way and maybe a short opinion on this issue, because there's no doubt that the pill that comes through the mail that causes the death of a baby is not safe for women.” — Jonathan Saenz, Texas Values
- “There are people who are facing intimate partner violence, and for them, it’s very difficult to visit a clinic and to get access, so medication abortion by telehealth is critically important for those individuals,” — Autumn Katz, Center for Reproductive Rights
- “It is like a giant chess game, in which we need to continue to keep trying to anticipate the next movement, and to overcome it to plan our next move,” — Melissa Grant, Carafem
What’s Next
The case will return to the 5th Circuit for further proceedings, and the FDA’s safety review is expected to conclude later in 2026. Both the Supreme Court and lower courts may revisit the issue before the 2026 midterm elections, when abortion policy remains a pivotal political factor.
